Pharmaphorum
Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine’s Xolremdi.
Pharmaphorum
Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine's Xolremdi.
Pharmaphorum
Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine’s Xolremdi.